Vertex gets FDA approval to expand ALYFTREK and TRIKAFTA to 95% of US CF patients

April 1, 2026 7:31 AM

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced that the U.S. Food and Drug Administration approved expanded use of its cystic fibrosis ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found